Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients
- Vauloup-Fellous, Christelle
- Maylin, Sarah
- Périllaud-Dubois, Claire
- Brichler, Ségolène
- Alloui, Chakib
- Gordien, Emmanuel
- Rameix-Welti, Marie-Anne
- Gault, Elyanne
- Moreau, Frédérique
- Fourati, Slim
- Challine, Dominique
- Pawlotsky, Jean-Michel
- Houhou-Fidouh, Nadhira
- Damond, Florence
- Mackiewicz, Vincent
- Charpentier, Charlotte
- Méritet, Jean-François
- Rozenberg, Flore
- Podglajen, Isabelle
- Marot, Stéphane
- Petit, Heloïse
- Burrel, Sonia
- Akhavan, Sepideh
- Leruez-Ville, Marianne
- Avettand-Fenoel, Véronique
- Fourgeaud, Jacques
- Guilleminot, Tiffany
- Gardiennet, Elise
- Bonacorsi, Stéphane
- Carol, Agnès
- Carcelain, Guislaine
- Villemonteix, Juliette
- Boukli, Narjis
- Gozlan, Joël
- Morand-Joubert, Laurence
- Legoff, Jérome
- Delaugerre, Constance
- Chaix, Marie-Laure
- Roque-Afonso, Ana-Maria
- Dortet, Laurent
- Naas, Thierry
- Ronat, Jean-Baptiste
- Lepape, Samuel
- Marcelin, Anne-Geneviève
- Descamps, Diane
Publication date
March 2021
DOI Publisher
Springer Science and Business Media LLCAbstract
International audienceWe report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation
Add to ORKG